Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProMetic Advances Lead Compound into Clinic | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

ProMetic Advances Lead Compound into Clinic

PBI-4050 passes fox testing, safe to advance

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

ProMetic Life Sciences’ lead candidate, PBI-4050, has successfully completed the required GLP toxicology studies performed by a certified CRO confirming that it is safe to advance into clinical trial stages.

Preclinical data on PBI-4050 confirms its potential as a novel therapy to inhibit inflammation and fibrosis which underlies progressive chronic renal diseases and pulmonary fibrosis, as well as fibrosis in other organs such as the liver and the heart. The company plans to commence Phase I trials this year and hopes to begin efficacy trials in 2014.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics